Patrick Chamouard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Patrick Chamouard has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
René Baumann
Hopital de Hautepierre
4 shared publicationsZoe Richert
Hopital de Hautepierre
2 shared publicationsAnne-Claire Voegeli
Hopital de Hautepierre
1 shared publicationBénédicte Hugel
Université Louis Pasteur
1 shared publicationCarole Gidon-Jeangirard
Université Louis Pasteur
1 shared publicationCorinne Kunzelmann
Université Louis Pasteur
1 shared publication
Latest Publications
- 3 December 2008
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 54 (10) , 2084-2093
Diminution of Circulating CD4+CD25high T Cells in Naïve Crohn’s Disease
Crohn’s disease is considered to be caused either by an excess of T-cell effector functions and/or by a defective regulatory T-cell compartment. The aim of this study was to assess in Crohn’s disease the frequency of circulating CD4+CD25high T cells that possess regulatory T-cell functions and CD4+CD25low T cells that contain activated T cells. Flow cytometry of peripheral blood was used to assess CD4+CD25high and CD4+CD25low T-cell frequencies in a cohort of 66 patients with Crohn’s disease in comparison to 19 patients with ulcerative colitis and 31 healthy individuals enrolled as controls. The CD4+CD25high T-cell frequency was significantly lowered in naïve Crohn’s disease (P = 0.013) and in ulcerative colitis (P = 0.001). CD4+CD25low T-cell frequency was increased in Crohn’s disease (P = 0.0001) and in ulcerative colitis (P = 0.0002). Both CD4+CD25high and CD4+CD25low T-cell frequencies are altered in naïve Crohn’s disease resulting in an imbalance between both populations and a relative contraction of the CD4+CD25high T-cell population.
- 3 December 2008
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 54 (10) , 2084-2093
Diminution of Circulating CD4+CD25high T Cells in Naïve Crohn’s Disease
Crohn’s disease is considered to be caused either by an excess of T-cell effector functions and/or by a defective regulatory T-cell compartment. The aim of this study was to assess in Crohn’s disease the frequency of circulating CD4+CD25high T cells that possess regulatory T-cell functions and CD4+CD25low T cells that contain activated T cells. Flow cytometry of peripheral blood was used to assess CD4+CD25high and CD4+CD25low T-cell frequencies in a cohort of 66 patients with Crohn’s disease in comparison to 19 patients with ulcerative colitis and 31 healthy individuals enrolled as controls. The CD4+CD25high T-cell frequency was significantly lowered in naïve Crohn’s disease (P = 0.013) and in ulcerative colitis (P = 0.001). CD4+CD25low T-cell frequency was increased in Crohn’s disease (P = 0.0001) and in ulcerative colitis (P = 0.0002). Both CD4+CD25high and CD4+CD25low T-cell frequencies are altered in naïve Crohn’s disease resulting in an imbalance between both populations and a relative contraction of the CD4+CD25high T-cell population.
- 1 July 2006
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (7) , 882-887
Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn’s Disease
- 1 July 2006
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (7) , 882-887
Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn’s Disease
- 1 December 2005
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 29 (12) , 1286-1288
Prolonged cholestasis associated with short-term use of celecoxib
- 1 December 2005
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 29 (12) , 1286-1288
Prolonged cholestasis associated with short-term use of celecoxib
- 1 March 2005
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 50 (3) , 574-580
Circulating Cell-Derived Microparticles in Crohn?s Disease
Procoagulant membrane microparticles can be released from activated or apoptotic cells in response to various environmental stimuli. The aim of this study was to investigate the presence of microparticles in Crohn’s disease and to assess their variations after infliximab therapy. We compared the levels of circulating microparticles in 38 patients with Crohn’s disease, 16 patients with ulcerative colitis, 7 patients with infectious colitis, and 17 control subjects. The evolution of microparticle levels was assessed after infliximab therapy in 13 patients with Crohn’s disease. Circulating microparticle levels were elevated in patients with Crohn’s disease (9.31 ± 0.66 nmol/L phosphatidylserine equivalent [PS Eq]) or infectious colitis (10.71 ± 0.92 nmol/L PS Eq) compared to patients with ulcerative colitis (5.75 ± 0.59 nmol/L PS Eq) and control subjects (4.06 ± 0.37 nmol/L PS Eq) (P = 0.001). Infliximab induced a significant diminution of the amounts of circulating microparticles, from 10.33 ± 1.20 to 6.45 ± 0.90 nmol/L PS Eq (P = 0.002). Generation of circulating microparticles occurs in Crohn’s disease; infliximab induces significant diminution. Release of microparticles could be linked to the type of inflammatory response underlying Crohn’s disease.
- 1 March 2005
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 50 (3) , 574-580
Circulating Cell-Derived Microparticles in Crohn?s Disease
Procoagulant membrane microparticles can be released from activated or apoptotic cells in response to various environmental stimuli. The aim of this study was to investigate the presence of microparticles in Crohn’s disease and to assess their variations after infliximab therapy. We compared the levels of circulating microparticles in 38 patients with Crohn’s disease, 16 patients with ulcerative colitis, 7 patients with infectious colitis, and 17 control subjects. The evolution of microparticle levels was assessed after infliximab therapy in 13 patients with Crohn’s disease. Circulating microparticle levels were elevated in patients with Crohn’s disease (9.31 ± 0.66 nmol/L phosphatidylserine equivalent [PS Eq]) or infectious colitis (10.71 ± 0.92 nmol/L PS Eq) compared to patients with ulcerative colitis (5.75 ± 0.59 nmol/L PS Eq) and control subjects (4.06 ± 0.37 nmol/L PS Eq) (P = 0.001). Infliximab induced a significant diminution of the amounts of circulating microparticles, from 10.33 ± 1.20 to 6.45 ± 0.90 nmol/L PS Eq (P = 0.002). Generation of circulating microparticles occurs in Crohn’s disease; infliximab induces significant diminution. Release of microparticles could be linked to the type of inflammatory response underlying Crohn’s disease.